Catalyst Biosciences Inc expected to post a loss of 10 cents a share - Earnings Preview

Gyre Therapeutics

08/11/2022 11:36

* Catalyst Biosciences Inc  CBIO.OQ   CBIO.O  is expected
to show
a fall in quarterly revenue when it reports  results on November
10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Catalyst
Biosciences Inc
is for a loss of 10 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Catalyst
Biosciences Inc is $16​, above​ its last closing price of $0.55.
​​​

This summary was machine generated November 8 at 11:36 GMT.  All
figures in US dollars  unless otherwise stated